BE680696A - - Google Patents

Info

Publication number
BE680696A
BE680696A BE680696A BE680696A BE680696A BE 680696 A BE680696 A BE 680696A BE 680696 A BE680696 A BE 680696A BE 680696 A BE680696 A BE 680696A BE 680696 A BE680696 A BE 680696A
Authority
BE
Belgium
Application number
BE680696A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT934165A external-priority patent/AT260240B/de
Application filed filed Critical
Publication of BE680696A publication Critical patent/BE680696A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
BE680696A 1965-05-08 1966-05-06 BE680696A (xx)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEC0035799 1965-05-08
DEC0037133 1965-10-12
DEC0037142 1965-10-13
AT934165A AT260240B (de) 1965-10-15 1965-10-15 Verfahren zur Herstellung von neuen Dikarbonsäureimidderivaten, sowie Salzen dieser Verbindungen

Publications (1)

Publication Number Publication Date
BE680696A true BE680696A (xx) 1966-11-07

Family

ID=27422273

Family Applications (1)

Application Number Title Priority Date Filing Date
BE680696A BE680696A (xx) 1965-05-08 1966-05-06

Country Status (8)

Country Link
BE (1) BE680696A (xx)
CH (1) CH478117A (xx)
FR (2) FR1592059A (xx)
GB (1) GB1075420A (xx)
IL (1) IL25595A (xx)
NO (1) NO123088B (xx)
OA (1) OA01951A (xx)
PH (1) PH10158A (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644066A (en) * 1968-09-18 1987-02-17 Raychem Corporation Flame retardants and compositions containing them
US4535170A (en) * 1968-09-18 1985-08-13 Raychem Corporation Flame retardants and compositions containing them
US4374220A (en) 1968-09-18 1983-02-15 Raychem Corporation Imide flame retardants and compositions containing them
US4581396A (en) * 1968-09-18 1986-04-08 Raychem Corporation Flame retardants and compositions containing them
DE2003608A1 (de) * 1970-01-28 1971-08-05 Gruenenthal Chemie Neue heterocyclische Verbindungen und Verfahren zu ihrer Herstellung
TR200101503T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
ES2172474B1 (es) * 2001-03-01 2004-01-16 Fundacion Universitaria San Pa Derivados de glutarimida como agentes terapeuticos.
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
SG133603A1 (en) 2003-09-17 2007-07-30 Us Gov Health & Human Serv Thalidomide analogs as tnf-alpha modulators
AU2007238785B2 (en) 2006-04-13 2013-02-07 Agnieszka Ambrozak Tetrahalogenated compounds useful as inhibitors of angiogenesis
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Also Published As

Publication number Publication date
GB1075420A (en) 1967-07-12
FR5806M (xx) 1968-02-19
NO123088B (xx) 1971-09-27
PH10158A (en) 1976-09-13
IL25595A (en) 1971-01-28
CH478117A (de) 1969-09-15
FR1592059A (xx) 1970-05-11
OA01951A (fr) 1970-02-04

Similar Documents

Publication Publication Date Title
DE1783151C3 (xx)
AU416352B2 (xx)
JPS4412199Y1 (xx)
BE674655A (xx)
BE668917A (xx)
BE675011A (xx)
NL6613170A (xx)
BE673319A (xx)
BE673452A (xx)
BE673710A (xx)
BE673719A (xx)
BE673764A (xx)
BE673847A (xx)
BE674077A (xx)
BE674208A (xx)
BE670896A (xx)
BE674337A (xx)
BE674455A (xx)
BE674458A (xx)
BE674476A (xx)
BE674605A (xx)
BE674615A (xx)
BE674635A (xx)
BE669733A (xx)
BE674825A (xx)